Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **combination of two herbal extracts**: Andrographis paniculata and Aristotelia chilensis. Andrographis paniculata is an annual herb from the Acanthaceae family, standardized to andrographolide, 14-deoxyandrographolide, and neo-andrographolide. It is widely used in traditional medicine for its anti-inflammatory, immunostimulant, antiviral, antibacterial, antidiabetic, and hepatoprotective properties. Aristotelia chilensis is the botanical source of Maqui berry, known for its high content of anthocyanidins (notably delphinidin) and long-standing traditional use for conditions such as sore throat, fever, and inflammation. The combination has been studied for the treatment of common cold and COVID-19-related symptoms, leveraging the immunomodulating and antioxidant activities of both components[1][2][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on andrographis paniculata + aristotelia chilensis.